Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0001140361-23-028539

Chief Operating Officer acquired 9,225 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Devroe Eric · Chief Operating Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-06-05 Exercise or conversion : show line 1 in the form +9,225 $1.04 $9,594 62,883 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-06-05 Exercise or conversion : show line 2 in the form Stock Option (Right to Buy) −9,225 96,615 D
Loading xslF345X04/form4.xml…